Toll Free: 1-888-928-9744

Liver Cirrhosis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Cirrhosis - Pipeline Review, H1 2016


Global Markets Direct's, 'Liver Cirrhosis - Pipeline Review, H1 2016', provides an overview of the Liver Cirrhosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Liver Cirrhosis Overview 9 Therapeutics Development 10 Pipeline Products for Liver Cirrhosis - Overview 10 Pipeline Products for Liver Cirrhosis - Comparative Analysis 11 Liver Cirrhosis - Therapeutics under Development by Companies 12 Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes 13 Liver Cirrhosis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Liver Cirrhosis - Products under Development by Companies 17 Liver Cirrhosis - Products under Investigation by Universities/Institutes 18 Liver Cirrhosis - Companies Involved in Therapeutics Development 19 Conatus Pharmaceuticals Inc. 19 Digna Biotech, S.L. 20 Galectin Therapeutics, Inc. 21 Gilead Sciences, Inc. 22 GNI Group Ltd. 23 Human Stem Cells Institute 24 INVENT Pharmaceuticals, Inc. 25 Nimbus Therapeutics, LLC 26 Pacific Therapeutics Ltd. 27 PharmaIN Corporation 28 Pharmicell Co., Ltd. 29 S-Evans Biosciences, Inc. 30 Stelic Institute & Co., Inc. 31 Stempeutics Research Private Limited 32 Liver Cirrhosis - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Target 35 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 (sofosbuvir + velpatasvir) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 DB-027 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 DB-036 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 emricasan - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 F-351 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Gemacell - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 GRMD-02 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 GXHPC-1 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 INV-340 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Livercellgram - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ND-654 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 PTL-303 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Stem Cell Therapy for Liver Cirrhosis - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Stempeucel - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 STNM-04 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Synthetic Peptide for Liver Cirrhosis - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 thrombopoietin - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Liver Cirrhosis - Recent Pipeline Updates 73 Liver Cirrhosis - Dormant Projects 90 Liver Cirrhosis - Discontinued Products 91 Liver Cirrhosis - Product Development Milestones 92 Featured News & Press Releases 92 Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 92 Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 93 Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 94 Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 94 Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 95 Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 95 May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 97 Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 98 Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 99 Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables
Number of Products under Development for Liver Cirrhosis, H1 2016 10 Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 19 Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H1 2016 20 Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 21 Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H1 2016 22 Liver Cirrhosis - Pipeline by GNI Group Ltd., H1 2016 23 Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2016 24 Liver Cirrhosis - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 25 Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H1 2016 26 Liver Cirrhosis - Pipeline by Pacific Therapeutics Ltd., H1 2016 27 Liver Cirrhosis - Pipeline by PharmaIN Corporation, H1 2016 28 Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H1 2016 29 Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H1 2016 30 Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H1 2016 31 Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H1 2016 32 Assessment by Monotherapy Products, H1 2016 33 Assessment by Combination Products, H1 2016 34 Number of Products by Stage and Target, H1 2016 36 Number of Products by Stage and Mechanism of Action, H1 2016 38 Number of Products by Stage and Route of Administration, H1 2016 40 Number of Products by Stage and Molecule Type, H1 2016 42 Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H1 2016 73 Liver Cirrhosis - Dormant Projects, H1 2016 90 Liver Cirrhosis - Discontinued Products, H1 2016 91

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.